CCL5 and metabolic syndrome: Discordant effects of RANTES in AD may possibly be explained by the RANTES binding and activating GPR75, a new target for metabolic syndrome and obesity (Murtaza et al., 2022), that may protect neuronal cells from Aβ toxicity (Ignatov et al., 2006) and regulate insulin secretion by pancreatic islet cells through activation of phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), and MAP kinases (Liu et al., 2013).